Literature DB >> 34422559

Ross operation after failure of aortic valve repair.

Karen B Abeln1, Vincent Chauvette2, Nancy Poirier2, Shunsuke Matsushima3, Ismail El-Hamamsy4, Hans-Joachim Schäfers1.   

Abstract

BACKGROUND: Repair failure remains one of the most important complications of aortic valve reconstruction. Young patients might benefit from a Ross procedure in such a scenario, provided it can be performed safely and with adequate durability. The aim of this study was to assess the safety and clinical outcomes of a Ross operation following a failed repair.
METHODS: Between 1996 and 2019, 80 patients (male, 76%; mean age, 31±13 years) underwent a Ross procedure after a median of 6.6 (1.7-15.9) years following an initial aortic valve repair. The previous valve repair was performed for unicuspid (53%), bicuspid (39%), tricuspid (7%), and quadricuspid morphology (1%). Median follow-up after the Ross operation was 2.8 (0.964-13.25) years, mean 5±5 years (92% complete).
RESULTS: Median cardiopulmonary bypass and cross-clamp times were 144 [106-154] minutes and 98 [79-113] minutes, respectively. Thirty-two patients (40%) required a concomitant procedure, most commonly, an ascending aortic replacement (n=23). There were no peri-operative deaths, myocardial infarctions, or neurological complications. There was one late death from a non-cardiac cause. At 10 years, overall survival was 99%±1%, similar to that of an age- and gender-matched population. Nine patients required re-intervention after their Ross procedure (five on the autograft and four on the pulmonary conduit). The autograft re-interventions were valve-sparing procedures in all patients. The cumulative incidence of re-intervention on the autograft at 8 years was 5.1%±3.1%.
CONCLUSIONS: The stepwise strategy of an initial valve repair followed by Ross operation represents a safe and valid option for failed aortic valve repair. It is associated with low peri-operative morbidity. Mid-term survival is excellent, similar to that of a matched general population. The probability of re-intervention after the Ross procedure appears similar to that of a primary Ross operation, deeming it a warranted consideration in cases of failed aortic valve repair. 2021 Annals of Cardiothoracic Surgery. All rights reserved.

Entities:  

Keywords:  Ross procedure; aortic regurgitation (AR); aortic valve repair; aortic valve repair failure; aortic valve replacement (AVR)

Year:  2021        PMID: 34422559      PMCID: PMC8339625          DOI: 10.21037/acs-2020-rp-19

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  33 in total

1.  Comparison of aortic valve gradient during exercise after aortic valve reconstruction.

Authors:  T P Graeter; M Kindermann; R Fries; F Langer; H J Schäfers
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

2.  Long-term durability of bicuspid aortic valve repair.

Authors:  Lars G Svensson; Adil H Al Kindi; Alessandro Vivacqua; Gösta B Pettersson; A Marc Gillinov; Tomislav Mihaljevic; Eric E Roselli; Joseph F Sabik; Brian Griffin; Donald F Hammer; Leonardo Rodriguez; Sarah J Williams; Eugene H Blackstone; Bruce W Lytle
Journal:  Ann Thorac Surg       Date:  2014-03-27       Impact factor: 4.330

3.  Fate of the aortic root late after Ross operation.

Authors:  Giovanni Battista Luciani; Gianluca Casali; Alessandro Favaro; Maria Antonia Prioli; Luca Barozzi; Francesco Santini; Alessandro Mazzucco
Journal:  Circulation       Date:  2003-09-09       Impact factor: 29.690

4.  Fourteen years' experience with 501 subcoronary Ross procedures: surgical details and results.

Authors:  Hans-H Sievers; Ulrich Stierle; Efstratios I Charitos; Thorsten Hanke; Armin Gorski; Martin Misfeld; Matthias Bechtel
Journal:  J Thorac Cardiovasc Surg       Date:  2010-03-17       Impact factor: 5.209

5.  Surgical anatomy of the aortic root: implication for valve-sparing reimplantation and aortic valve annuloplasty.

Authors:  Laurent de Kerchove; Ramadan Jashari; Munir Boodhwani; Khanh Tran Duy; Benoit Lengelé; Pierre Gianello; Zahra Mosala Nezhad; Parla Astarci; Philippe Noirhomme; Gebrine El Khoury
Journal:  J Thorac Cardiovasc Surg       Date:  2014-09-18       Impact factor: 5.209

6.  Repair of the bicuspid aortic valve: a viable alternative to replacement with a bioprosthesis.

Authors:  Elena Ashikhmina; Thoralf M Sundt; Joseph A Dearani; Heidi M Connolly; Zhuo Li; Hartzell V Schaff
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-14       Impact factor: 5.209

7.  The Ross procedure using autologous support of the pulmonary autograft: techniques and late results.

Authors:  Peter D Skillington; M Mostafa Mokhles; Johanna J M Takkenberg; Marco Larobina; Michael O'Keefe; Rochelle Wynne; James Tatoulis
Journal:  J Thorac Cardiovasc Surg       Date:  2014-09-17       Impact factor: 5.209

8.  Aortic valve repair leads to a low incidence of valve-related complications.

Authors:  Diana Aicher; Roland Fries; Svetlana Rodionycheva; Kathrin Schmidt; Frank Langer; Hans-Joachim Schäfers
Journal:  Eur J Cardiothorac Surg       Date:  2009-07-29       Impact factor: 4.191

9.  Comparison of Hemodynamics After Aortic Root Replacement Using Valve-Sparing or Bioprosthetic Valved Conduit.

Authors:  Jeremy D Collins; Edouard Semaan; Alex Barker; Patrick M McCarthy; James C Carr; Michael Markl; S Chris Malaisrie
Journal:  Ann Thorac Surg       Date:  2015-07-23       Impact factor: 4.330

10.  Late results of the Ross procedure.

Authors:  Tirone E David; Maral Ouzounian; Carolyn M David; Myriam Lafreniere-Roula; Cedric Manlhiot
Journal:  J Thorac Cardiovasc Surg       Date:  2018-07-18       Impact factor: 5.209

View more
  1 in total

1.  Comparison of bicuspidization and Ross procedure in the treatment of unicuspid aortic valve disease in adults - Insight from the AVIATOR registry.

Authors:  Ján Gofus; Mikita Karalko; Petr Fila; Jiří Ondrášek; Hans-Joachim Schäfers; Adrian Kolesár; Emmanuel Lansac; Ismail El-Hamamsy; Laurent de Kerchove; Christian Dinges; Jaroslav Hlubocký; Petr Němec; Martin Tuna; Jan Vojáček
Journal:  Front Cardiovasc Med       Date:  2022-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.